BACKGROUND AND OBJECTIVES: Disparities between tumors arising via different sporadic carcinogenetic pathways have not been studied systematically. This retrospective multicenter cohort study evaluated the differences in the risk for non-colorectal malignancy between sporadic colorectal cancer (CRC) patients from different DNA mismatch repair status. METHODS: A retrospective European multicenter cohort study including in total of 1706 CRC patients treated between 1996 and 2019 in three different countries. The proficiency (pMMR) or deficiency (dMMR) of mismatch repair was determined by immunohistochemistry. Cases were analyzed for tumor BRAFV600E mutation, and BRAF mutated tumors were further analyzed for hypermethylation status in the promoter region of MLH1 to distinguish between sporadic and hereditary cases. Swedish and Finish patients were matched with their respective National Cancer Registries. For the Czech cohort, thorough scrutiny of medical files was performed to identify any non-colorectal malignancy within 20 years before or after the diagnosis of CRC. Poisson regression analysis was performed to identify the incidence rates of non-colorectal malignancies. For validation purposes, standardized incidence ratios were calculated for the Swedish cases adjusted for age, year, and sex. RESULTS: Of the 1706 CRC patients included in the analysis, 819 were female [48%], median age at surgery was 67 years [interquartile range: 60-75], and sporadic dMMR was found in 188 patients (11%). Patients with sporadic dMMR CRC had a higher incidence rate ratio (IRR) for non-colorectal malignancy before and after diagnosis compared to patients with a pMMR tumor, in both uni- (IRR = 2.49, 95% confidence interval [CI] = 1.89-3.31, p = 0.003) and multivariable analysis (IRR = 2.24, 95% CI = 1.67-3.01, p = 0.004). This association applied whether or not the non-colorectal tumor developed before or after the diagnosis of CRC in both uni- (IRR = 1.91, 95% CI = 1.28-2.98, p = 0.004), (IRR = 2.45, 95% CI = 1.72-3.49, p = 0.004) and multivariable analysis (IRR = 1.67,95% CI = 1.05-2.65, p = 0.029), (IRR = 2.35, 95% CI = 1.63-3.42, p = 0.005), respectively. CONCLUSION: In this retrospective European multicenter cohort study, patients with sporadic dMMR CRC had a higher risk for non-colorectal malignancy than those with pMMR CRC. These findings indicate the need for further studies to establish the need for and design of surveillance strategies for patients with dMMR CRC.

Department of Clinical Oncology Comprehensive Oncology Center Liberec Czech Republic

Department of Gastrointestinal Surgery University of Helsinki and Helsinki University Hospital Helsinki Finland

Department of Medical Biosciences Pathology Umeå University Umeå Sweden

Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology and Radiotherapy Faculty Hospital Pilsen Charles University Prague Czech Republic

Department of Oral Pathology and Radiology University of Turku Turku Finland

Department of Pathology Regional Hospital of Liberec Liberec Czech Republic

Department of Pathology University of Helsinki Helsinki Finland

Department of Radiation Sciences Umeå University Umeå Sweden

Department of Surgical and Perioperative Sciences Surgery Umeå University Umeå Sweden

Department of Transplantation and Liver Surgery University of Helsinki and Helsinki University Hospital Helsinki Finland

Zobrazit více v PubMed

Mattiuzzi C, Sanchis‐Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med. 2019;7(21):609.

American Cancer Society. Colorectal Cancer. 2019, Accessed July 4, 2019. https://www.cancer.org/cancer/colon-rectal-cancer.html

International Agency for Research on Cancer. International Agency for Research on Cancer, Accessed July 4, 2019. https://gco.iarc.fr/today/fact-sheets-cancers.

Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. Gastroenterology. 2020;158(2):291‐302.

Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13(1):120‐135.

Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58(15):3455‐3460.

Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Fam Cancer. 2019;18(2):211‐219.

Pellat A, Netter J, Perkins G, et al. Lynch syndrome: what is new? Bull Cancer. 2018;106(7‐8):647‐655.

Velho S. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014;20(44):16433.

Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol. 2006;24(11):1745‐1753.

Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas. Am J Pathol. 2000;156(5):1641‐1651.

Goeppert B, Roessler S, Renner M, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non‐liver fluke associated cholangiocarcinoma. Br J Cancer. 2019;120(1):109‐114.

Fritz AG. International classification of diseases for oncology: ICD‐O. World Health Organization; 2013.

Lynch H, Lynch P, Lanspa S, Snyder C, Lynch J, Boland C. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1‐18.

Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043‐1048.

Vasen H, Watson P, Mecklin J, Lynch H. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453‐1456.

Gkekas I, Novotny J, Fabian P, et al. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients. Eur J Surg Oncol. 2019;45(10):1854‐1861.

Benlloch S, Payá A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer. J Mol Diagn. 2006;8(5):540‐543.

Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013;463(5):613‐621.

Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008;129(7‐8):391‐407.

Wang L‐H, Wu C‐F, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: an overview. Cell Physiol Biochem. 2018;51(6):2647‐2693.

Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumor‐suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009‐6015.

Zhang Y, Herman B. Ageing and apoptosis. Mech Ageing Dev. 2002;123(4):245‐260.

Anisimov VN. The relationship between aging and carcinogenesis: a critical appraisal. Crit Rev Oncol Hematol. 2003;45(3):277‐304.

Coolbaugh‐Murphy MI, Xu J, Ramagli LS, et al. Microsatellite instability (MSI) increases with the age of normal individuals and supports the significance of higher MSI levels in constitutive tissues of HNPCC patients, In: AACR 2005.

Chang C‐C, Lin P‐C, Lin C‐C, et al. Molecular and clinicopathological differences by age at the diagnosis of colorectal cancer. Int J Mol Sci. 2017;18(7):1441.

Jiricny J. The multifaceted mismatch‐repair system. Nat Rev Mol Cell Biol. 2006;7(5):335‐346.

Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology. 2009;136(3):780‐798.

National Cancer Registry I. Why are data for non‐melanoma skin cancer sometimes excluded? 2014; Accessed December 12, 2014. https://www.ncri.ie/faqs/interpret-use-our-data/why-are-data-non-melanoma-skin-cancer-sometimes-excluded.

Yurgelun MB, Hampel H. Recent advances in lynch syndrome: diagnosis, treatment, and cancer prevention. Am Soc Clin Oncol Educ Book. 2018;38:101‐109.

Rodríguez–Soler M, Pérez–Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144(5):926‐932.e1.e921.

Cherubini A, Pierri F, Gasperini B, et al. Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica. 2013;98(7):997‐1000.

Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14‐22.

Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25(33):5158‐5164.

Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464‐472.

Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer. 2013;12(2):229‐240.

Chen E, Xu X, Liu T. Hereditary nonpolyposis colorectal cancer and cancer syndromes: recent basic and clinical discoveries. J Oncol. 2018;2018:2018.

Bucksch K, Zachariae S, Aretz S, et al. Cancer risks in Lynch syndrome, Lynch‐like syndrome, and familial colorectal cancer type X: a prospective cohort study. BMC Cancer. 2020;20:460.

Liu G‐C, Liu R‐Y, Yan J‐P, et al. The heterogeneity between Lynch‐associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst. 2018;110(9):975‐984.

Paschke S, Jafarov S, Staib L, et al. Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci. 2018;19(9):2577.

Eklöf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013;108(10):2153‐2163.

Nilsson E, Orwelius L, Kristenson M. Patient‐reported outcomes in the swedish national quality registers. In. Vol 279. Wiley Online Library; 2016:141‐153.